Another CPT Code Approved for Cleerly’s Advanced Plaque Analysis Tool

The American Medical Association (AMA) has approved another CPT Category I code for Cleerly’s artificial intelligence-QCT advanced plaque analyses. The code is set to take effect on Jan. 1, 2026.

The newly assigned CPT code signifies a transition from the Category III codes approved in 2020, which were intended as a temporary measure while additional data was gathered, Cleerly claims. Category I codes are reserved for established medical procedures and technologies, providing permanent recognition that facilitates broader adoption, coverage and reimbursement across healthcare systems.

“We are delighted the American Medical Association has officially approved our request for a CPT Category I code for Cleerly’s AI-QCT advanced plaque analyses,” Cleerly Founder/CEO Dr. James K. Min said. “Our team at Cleerly initiated this process with the AMA more than five years ago, and we could not be more thankful to the many societies and physicians that have supported us in the process. This approval shows the importance and power of AI and advanced imaging technologies in clinical practice. It’s been a very exciting time here at Cleerly—beyond the Category I CPT Code, we also saw five of seven Medicare Administrative Contractors finalize a coverage determination for Cleerly’s advanced plaque analysis. Both of these decisions will significantly expand the access of our personalized heart disease technology to Medicare beneficiaries and will encourage a paradigm shift in cardiovascular care.”

Cleerly remains committed to advancing cardiovascular evaluation through noninvasive advanced imaging to improve patient outcomes.

Cleerly is striving to create a new standard of care for heart disease. Through its U.S. Food and Drug Administration-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive computed tomography imaging. Cleerly’s approach is grounded in science, based on millions of images from more than 40,000 patients. Led by a clinical and technical team, Cleerly enhances health literacy for every stakeholder in the coronary care pathway.